This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its largest events of the year. With the acquisition, the pharma giant will get Intra-Cellular’s Caplyta, which is approved to treat schizophrenia and bipolar-related depression.
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.
Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the Truveta Genome Project , a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs. Truveta plans to use leftover biospecimens from patients — after they consent — receiving routine health care at participating health systems to create the database.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.
GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.
A combination of ibuprofen and acetaminophen was found to be superior to hydrocodone and acetaminophen in managing pain after impacted mandibular third-molar extraction surgery.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
As deadly fires continue to rage in Los Angeles, healthcare companies far and wide are stepping up to serve those affected. At least 24 people have died from the fires and dozens remain missing.
A recent confluence of events marks the first time in decades that there's been indication of real, meaningful change to the system, writes Blue Shield of California's Matthew Gibbs.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Though largely comprised of nurses, the walk-off that began Friday also includes physician associates and doctorsthe latter of which is a first for Oregon, per the Oregon Nurses Association.
The pending purchase values Access Healthcare at roughly $2 billion, per Bloomberg, and builds on the private equity firm's recent revenue cycle management dealmaking.
The three largest Pharmacy Benefit Managers (PBMs) continue to abuse the health care system, significantly marking up a wide range of lifesaving medicines according to a new report from the Federal Trade Commission (FTC).
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
A compounded medication is a custom formulation of an existing brand-name or generic drug made by a licensed pharmacist and designed to meet a patients unique needs. For example, a person who is allergic to a common dye included in a prescription drug could have a compounded version of the drug made without that dye. More notably, compounded drugs are also made to counteract drug shortages.
SCAN Group will make a strategic investment in Cresta, which has built a generative AI platform for contact centers, the insurer told Fierce Healthcare exclusively.
If you or someone you know experiences weight-related challenges or Type 2 diabetes, medications like Zepbound and Mounjaro might be part of the conversation when it comes to treatment options. These medications both involve a weekly injection and share the same active ingredient, tirzepatide. As a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide can help control appetite and decrease sugar levels.
The two companies will co-develop and deploy integrated AI-driven products that address needs across predictive and personalized care, interoperability, efficiency, diagnostics and patient engagement.
Discover how data science and AI are set to revolutionise the life sciences industry by 2025, with a focus on mRNA technology and CRISPR gene editing. Stay ahead of the curve with these cutting-edge advancements.
The AI task force will release a report on AI-powered ambient scribes and revenue cycle management tools in the first quarter. A goal of the report is to provide guidance to healthcare organizations on how to track the efficacy of the tools.
Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.
The 16-hospital system stressed that it isn't going out of business, but is using the bankruptcy process to streamline much-needed divestitures. The company was recently in the crosshairs of a bipartisan Senate report critical of longtime private equity owner, Leonard Green & Partners.
The designation was supported by data from the phase 2, open-label, randomized, multi-center ARTEMIS-002 clinical trial, which assessed the safety and efficacy of GSK227.
Under this program, Advocate Health intends to "rewire" its operations as it looks to the future of healthcare, CEO Eugene Woods said during a session at the J.P. Morgan Healthcare Conference on Monday.
Rock Health's annual report outlines key trends in VC funding: a handful of large, more established players dominated healthcare innovation headlines, heavyweight investors drove sector dealmaking and digital health startups turned to M&A to build out their offerings.
77
77
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
129 
Let's personalize your content